Burgeon
Burgeon Biotechnology is a privately held Turkish medical aesthetics company that develops and globally distributes CaHA-based biostimulatory and HA-based dermal fillers for dermatologists, plastic surgeons, and aesthetic practitioners, exporting to 45+ countries across Latin America, Asia-Pacific, the Middle East, and Europe.
- Company typePrivate
- Founded2017
- HeadquartersAnkara
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Burgeon does
Burgeon Biotechnology (Burgeon Biyoteknoloji ve San. Tic. A.Ş.) is a privately held Turkish medical aesthetics company founded in 2017 within the BMT Group and headquartered in Ankara, Turkey. The company develops, manufactures, and globally distributes biostimulatory dermal fillers for dermatologists, plastic surgeons, and aesthetic medicine practitioners. Its product portfolio spans three technology platforms: NOVUMA, a calcium hydroxyapatite (CaHA) mineral-based biostimulator that stimulates natural collagen and elastin production; CALHYDRA (and CALHYDRA LIFT), a hybrid dermal filler kit combining CaHA biostimulation with hyaluronic acid (HA); and the Youth Support Series, an HA-based filler line (CORINTHA, TUSCAN, IONA, DORA) targeting different tissue depths from superficial fine-line correction to deep facial contouring. Differentiated technical features include High Microsphere Density (up to 10% more microspheres than competitor products), Harmonophasic Technology for balanced tissue distribution, Tissue-Mimetic Design to minimize foreign body reactions, and a Density Control System allowing physicians to adjust product density by treatment area.
Burgeon operates an enterprise field-sales motion targeting medical aesthetic practitioners, complemented by regional distributor networks and a strategic distribution alliance with Laboratoires VIVACY (France) for European market access. NOVUMA holds EU MDR 2017/745 Class III, Annex XVI certification, placing Burgeon among a select group of European companies cleared at this regulatory level for CaHA fillers. The company exports to 45+ countries across Latin America, Asia-Pacific, the Middle East, and Europe, with revenue generated from one-time product sales and licensing/distribution partnerships. Beyond commercial sales, Burgeon operates E-Academy for professional training and the Renova Touch social responsibility program that applies NOVUMA to facial paralysis rehabilitation. Notable third-party validation includes a 2025 Platinum at the Communitas Awards (USA) and a 2025 Gold at the MarCom Awards for the Renova Touch program. The company is led by founders Levent Mete Özgürbüz and Derya Özgürbüz.
The business model combines direct enterprise sales, distributor/wholesale channels, and a channel/reseller arrangement with VIVACY. Pricing is not publicly disclosed and is set downstream by clinics and practitioners. The company has not disclosed external venture funding, ownership stakes, or financial results; ownership remains with the BMT Group parent, supporting a financially stable operating base. Headcount is in the 51–100 range, with women representing more than 60% of the workforce and significant R&D representation, and manufacturing is conducted in-house at Ankara-based facilities with clean-room capability.
Burgeon firmographics
Firmographics- Name
- Burgeon
- Legal name
- Burgeon Biyoteknoloji ve San. Tic. A.Ş
- Website
- https://burgeon.me
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Burgeon Biotechnology is a privately held Turkish medical aesthetics company that develops and globally distributes CaHA-based biostimulatory and HA-based dermal fillers for dermatologists, plastic surgeons, and aesthetic practitioners, exporting to 45+ countries across Latin America, Asia-Pacific, the Middle East, and Europe.
- Ownership category
- akta.pro rank
Burgeon industry classification
Industry- Product category
- Medical Aesthetic Dermal Fillers
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Dermocosmetics & Medical-Grade Skincare (CRABAAAF)
- akta.pro secondary industry
- Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)
Keywords
Where Burgeon is headquartered
LocationHeadquarters
- HQ city
- Ankara
Offices1 record
Markets served
Burgeon business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- Dermal Filler Products: Revenue generated from sale of biostimulatory dermal fillers including NOVUMA (CaHA-based), CALHYDRA (hybrid CaHA/HA), and Youth Support Series (HA-based). Products are sold to healthcare professionals and clinics globally.
- Licensing and Distribution Partnerships: Strategic partnerships such as the VIVACY alliance for European market distribution generate revenue through product licensing and distribution arrangements.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels7 records
Burgeon product offering
Product offeringCore offering
Burgeon Biotechnology develops and manufactures biostimulatory and hyaluronic acid-based dermal fillers for the medical aesthetics industry. Its product portfolio centers on NOVUMA (a calcium hydroxyapatite-based biostimulator), CALHYDRA and CALHYDRA Lift (hybrid CaHA/HA dermal filler kits), and the Youth Support Series (HA-based fillers across four densities). Products are sold to dermatologists, plastic surgeons, and aesthetic medicine practitioners worldwide.
Product overview
Burgeon is a biotechnology company specializing in advanced biostimulatory dermal fillers and aesthetic solutions. The product portfolio centers on three main product lines: Novuma (CaHA-based biostimulator), Calhydra/Calhydra Lift (hybrid dermal filler kits combining CaHA and hyaluronic acid), and the Youth Support Series (HA-based fillers in four densities: CORINTHA, TUSCAN, IONA, and DORA). The products are designed for subcutaneous application to address skin aging signs including wrinkles, dryness, and sagging. The company also operates E-Academy for professional education and runs Renova Touch as a social responsibility initiative.
Differentiator
Problem solved
Functional benefit
Brands
- Novuma: Mineral-based dermal filler with CaHA (Calcium Hydroxyapatite) that combats wrinkles, dryness, and sagging by stimulating collagen and elastin production.
- Calhydra
- Calhydra Lift
- Youth Support Series
- Renova Touch
- E-Academy
Products and services
- NOVUMA Mineral-based dermal filler containing calcium hydroxyapatite (CaHA) microspheres that combats wrinkles, dryness, and sagging by stimulating natural collagen and elastin production for skin regeneration. Designed for subcutaneous application by medical aesthetic practitioners.
- Youth Support Series Hyaluronic acid (HA)-based dermal filler series designed to restore disrupted moisture balance and rebuild lost volume in subdermal layers. Includes four specialized products: CORINTHA for fine lines and minor skin damage, TUSCAN for lip enhancement, IONA for mid-face and deep wrinkles, and DORA for facial contouring of cheekbones, chin, and jawline. Features Harmonophasic Technology and Tissue-Mimetic Design for natural tissue integration.
Quantifiable outcome
- Microsphere effects begin at 8 weeks post-application with optimal results visible at 3 months
- +2 more outcomes
Companies that use Burgeon
Customer profileNamed customers7 records
Segments2 records
Ideal customer profiles1 record
Burgeon technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Burgeon partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Laboratoires VIVACYcoreStrategic collaboration signed March 26, 2025 combining Burgeon's NOVUMA CaHA biostimulator technology with VIVACY's STYLAGE hyaluronic acid dermal fillers. The partnership aims to provide aesthetically-trained physicians with scientifically innovative and clinically proven solutions for skin rejuvenation. VIVACY will distribute NOVUMA first in Europe, then expand to other regions. The alliance leverages two advanced technology platforms to meet evolving patient needs.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Burgeon competitors and assessment
Company assessmentBroad incumbents
- AbbVie Allergan Aesthetics: Owns the Juvéderm HA filler franchise and broader aesthetics portfolio (Botox, CoolSculpting); a large incumbent Burgeon competes against in the same dermatologist and plastic-surgeon channels.
Direct peers
- Galderma: Global aesthetics leader with Sculptra (CaHA-based biostimulator) and the Restylane HA filler portfolio — the closest direct competitor to Burgeon's Novuma and Youth Support Series across medical-aesthetic injectables.
- Merz Aesthetics: Markets Radiesse (CaHA biostimulator) and Belotero (HA fillers), making it a head-to-head CaHA competitor to Novuma and a direct peer in physician-channel injectable aesthetics.
- Laboratoires VIVACY: French aesthetics company behind STYLAGE HA dermal fillers; Burgeon's European distribution partner and a direct peer in HA fillers, giving insight into how the partner's portfolio overlaps and competes with Youth Support Series.
- Teoxane: Swiss-based aesthetics specialist with the Teosyal range of HA dermal fillers; comparable mid-sized European player targeting the same dermatology and plastic-surgery customer base as Burgeon's Youth Support Series.
- Sinclair Pharma: European aesthetics company with HA filler and bio-stimulator offerings (e.g., MaiLi, Ellansé); a comparable mid-cap peer operating in the same injectable-aesthetics category and channels.
- Croma-Pharma: Austrian manufacturer of Princess HA dermal fillers and aesthetics injectables; similar profile to Burgeon as a privately held European aesthetics manufacturer with global export ambitions.
Emerging players
- Revance Therapeutics: U.S.-listed aesthetics company behind the RHA Collection of HA fillers and DAXXIFY; a focused injectable-aesthetics peer operating in the same dermatologist/plastic-surgeon channel with a biostimulation-adjacent positioning.
- Evolus: U.S. aesthetics company focused on injectable neuromodulators and expanding into fillers; an emerging direct competitor in the medical-aesthetics channel Burgeon serves.
Regional players
- Huons Global: South Korean aesthetics and biopharmaceutical company with HA dermal fillers (e.g., Elravie) competing in the same injectable category, primarily in APAC markets where Burgeon is also expanding distribution.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Burgeon social profiles
Digital presenceBurgeon compliance and trust
Trust signalCompliance2 records
Burgeon financial estimates
Financial estimateRevenue estimate
Valuation estimate
Burgeon leadership team
Management profileNumber of profiles
Profiles3 records
Burgeon funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Burgeon M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Burgeon
What does Burgeon do?
Burgeon Biotechnology develops and manufactures biostimulatory and hyaluronic acid-based dermal fillers for the medical aesthetics industry. Its product portfolio centers on NOVUMA (a calcium hydroxyapatite-based biostimulator), CALHYDRA and CALHYDRA Lift (hybrid CaHA/HA dermal filler kits), and the Youth Support Series (HA-based fillers across four densities). Products are sold to dermatologists, plastic surgeons, and aesthetic medicine practitioners worldwide.
Is Burgeon a public or private company?
Burgeon is a private company. It is classified as corporate owned and is currently operating.
When was Burgeon founded?
Burgeon was founded in 2017. It employs 11 to 50 people.
Where is Burgeon based?
Burgeon is headquartered in Ankara.
How does Burgeon make money?
Two revenue lines are on record. Dermal Filler Products are the primary driver. The others are licensing and Distribution Partnerships.
Who are Burgeon's main competitors?
AbbVie Allergan Aesthetics is listed as a broad incumbent. Direct peers are Galderma, Merz Aesthetics, Laboratoires VIVACY, Teoxane, Sinclair Pharma and Croma-Pharma. Emerging players are Revance Therapeutics and Evolus. Huons Global is listed as a regional player.
Does Burgeon have an API?
No public API is recorded for Burgeon.
What industry is Burgeon in?
Burgeon's product category is Medical Aesthetic Dermal Fillers. Its primary akta.pro industry code is CRABAAAF, Dermocosmetics & Medical-Grade Skincare, with a secondary code of HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes). Its NAICS code is 339113 and its SIC code is 3841.